157 related articles for article (PubMed ID: 32047498)
1. Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates.
Qin M; Wang L; Wu D; Williams CK; Xu D; Kranz E; Guo Q; Guan J; Vinters HV; Lee Y; Xie Y; Luo Y; Sun G; Sun X; He Z; Lu Y; Kamata M; Wen J; Chen ISY
Front Immunol; 2019; 10():3132. PubMed ID: 32047498
[TBL] [Abstract][Full Text] [Related]
2. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice.
Wen J; Wu D; Qin M; Liu C; Wang L; Xu D; Vinters HV; Liu Y; Kranz E; Guan X; Sun G; Sun X; Lee Y; Martinez-Maza O; Widney D; Lu Y; Chen ISY; Kamata M
Nat Biomed Eng; 2019 Sep; 3(9):706-716. PubMed ID: 31384008
[TBL] [Abstract][Full Text] [Related]
3. Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
Miyake Y; Okoshi Y; Machino T; Chiba S
Int J Hematol; 2010 Oct; 92(3):474-80. PubMed ID: 20820968
[TBL] [Abstract][Full Text] [Related]
4. A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System.
Wu D; Qin M; Xu D; Wang L; Liu C; Ren J; Zhou G; Chen C; Yang F; Li Y; Zhao Y; Huang R; Pourtaheri S; Kang C; Kamata M; Chen ISY; He Z; Wen J; Chen W; Lu Y
Adv Mater; 2019 May; 31(18):e1807557. PubMed ID: 30803073
[TBL] [Abstract][Full Text] [Related]
5. Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy.
Han L; Liu C; Qi H; Zhou J; Wen J; Wu D; Xu D; Qin M; Ren J; Wang Q; Long L; Liu Y; Chen I; Yuan X; Lu Y; Kang C
Adv Mater; 2019 May; 31(19):e1805697. PubMed ID: 30773720
[TBL] [Abstract][Full Text] [Related]
6. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
[TBL] [Abstract][Full Text] [Related]
7. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
8. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
[TBL] [Abstract][Full Text] [Related]
10. Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma.
Thumrongsiri N; Dana P; Bawab R; Tanyapanyachon P; Treetidnipa C; Saengkrit N; Sathornsumetee S
Biomed Pharmacother; 2022 Jun; 150():112979. PubMed ID: 35461090
[TBL] [Abstract][Full Text] [Related]
11. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
[TBL] [Abstract][Full Text] [Related]
12. Unique therapeutic properties and preparation methodology of multivalent rituximab-lipid nanoparticles.
Popov J; Gilabert-Oriol R; Bally MB
Eur J Pharm Biopharm; 2017 Aug; 117():256-269. PubMed ID: 28450189
[TBL] [Abstract][Full Text] [Related]
13. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
15. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
16. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
17. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
[TBL] [Abstract][Full Text] [Related]
20. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
